Literature DB >> 1440702

Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism.

J Pedro-Botet1, M Sentí, X Nogués, J Rubiés-Prat, J Roquer, L D'Olhaberriague, J Olivé.   

Abstract

BACKGROUND AND
PURPOSE: The role of lipoprotein abnormalities in the development of ischemic cerebrovascular disease has not been sufficiently clarified. The aim of this study was to identify the lipoprotein profile in ischemic cerebrovascular disease and the possible role of apolipoprotein E polymorphism.
METHODS: The relation between the concentrations of lipoprotein(a), intermediate density lipoproteins, apolipoprotein A-I, apolipoprotein B, apolipoprotein E, and other lipoproteins was studied in 100 men with ischemic cerebrovascular disease (48 atherothrombotic, 28 lacunar, and 24 of unknown type) and in 100 healthy age-matched men as a control group.
RESULTS: Patients with ischemic cerebrovascular disease had significantly higher levels of lipoprotein(a), lipids carried by intermediate density lipoproteins, and low density lipoprotein cholesterol and lower levels of high density lipoproteins than control subjects. Patients with atherothrombotic infarction had higher total serum cholesterol and low density lipoprotein cholesterol concentrations than patients with lacunar infarction. To assess lipoprotein abnormalities in normolipidemic subjects, a subgroup of 38 patients with ischemic cerebrovascular disease and 53 control subjects, both with serum cholesterol levels < 5.2 mmol/l (200 mg/dl) and triglycerides < 2.3 mmol/l (200 mg/dl), was analyzed. Serum lipoprotein(a), lipids carried by very low density lipoproteins and intermediate density lipoproteins, and low density lipoprotein triglycerides were significantly higher in normolipidemic patients compared with normolipidemic control subjects, whereas high density lipoprotein cholesterol levels were lower. Apolipoprotein E polymorphism in our ischemic cerebrovascular patients differed from that of the control group, with the epsilon 4 allele being more prevalent.
CONCLUSIONS: Increased serum lipoprotein(a) levels and intermediate density lipoprotein abnormalities together with decreased high density lipoprotein levels are major risk factors for ischemic cerebrovascular disease, even in normocholesterolemic and normotriglyceridemic subjects. Finally, the epsilon 4 allele could probably be a predisposing genetic marker for ischemic cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1440702     DOI: 10.1161/01.str.23.11.1556

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  21 in total

Review 1.  The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.

Authors:  C Sarti; M Kaarisalo; J Tuomilehto
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype.

Authors:  H Payami; H Grimslid; B Oken; R Camicioli; G Sexton; A Dame; D Howieson; J Kaye
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

Review 3.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

4.  Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population.

Authors:  Furcy Paultre; Catherine H Tuck; Bernadette Boden-Albala; Douglas E Kargman; Elizabeth Todd; Jeffrey Jones; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-01       Impact factor: 8.311

5.  Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke.

Authors:  Viktória Havasi; Zoltán Szolnoki; Gábor Talián; Judit Bene; Katalin Komlósi; Anita Maász; Ferenc Somogyvári; András Kondacs; Mihály Szabó; Lajos Fodor; Anita Bodor; Béla Melegh
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

6.  Triglyceride level-influencing functional variants of the ANGPTL3, CILP2, and TRIB1 loci in ischemic stroke.

Authors:  Luca Járomi; Veronika Csöngei; Noémi Polgár; Gábor Rappai; Zoltán Szolnoki; Anita Maász; Katalin Horvatovich; Eniko Sáfrány; Csilla Sipeky; Lili Magyari; Béla Melegh
Journal:  Neuromolecular Med       Date:  2011-06-21       Impact factor: 3.843

7.  Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia.

Authors:  J Kawamata; S Tanaka; S Shimohama; K Ueda; J Kimura
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women.

Authors:  H Payami; S Zareparsi; K R Montee; G J Sexton; J A Kaye; T D Bird; C E Yu; E M Wijsman; L L Heston; M Litt; G D Schellenberg
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

9.  Polymorphism of angiotensin-converting enzyme, angiotensinogen, and apolipoprotein E genes in Korean patients with cerebral infarction.

Authors:  Jae-Young Um; Kyung-Suk Moon; Kang-Min Lee; Kwang-Ho Cho; Yun Heo; Byung-Soon Moon; Hyung-Min Kim
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

10.  Intercellular adhesion molecule-1 gene K469E polymorphism and ischemic stroke: a case-control study in a Chinese population.

Authors:  Xiao Xia Li; Jian Ping Liu; Jin Quan Cheng; Sheng Hong Han; Yi Jie Geng; Sheng Wei; Shi Tong Gao; Da Na Huang; Shao Fa Nie
Journal:  Mol Biol Rep       Date:  2008-09-14       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.